James Kramer
Overview
Explore the profile of James Kramer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
401
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delaunois A, Abernathy M, Anderson W, Beattie K, Chaudhary K, Coulot J, et al.
Clin Transl Sci
. 2021 Feb;
14(3):1133-1146.
PMID: 33620150
We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine...
2.
Rosasco J, Hanson Z, Kramer J, Steele L, Beachy B, David Gothard M, et al.
Telemed J E Health
. 2020 Oct;
27(7):755-762.
PMID: 33090088
The events of the coronavirus disease 2019 (COVID-19) pandemic forced the world to adopt telemedicine frameworks to comply with isolation and stay-at-home regulations. Telemedicine, in various forms, has been used...
3.
Kramer J, Himmel H, Lindqvist A, Stoelzle-Feix S, Chaudhary K, Li D, et al.
Sci Rep
. 2020 Jul;
10(1):11884.
PMID: 32665705
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
4.
Han X, Samieegohar M, Ridder B, Wu W, Randolph A, Tran P, et al.
J Pharmacol Toxicol Methods
. 2020 Jun;
105:106890.
PMID: 32574700
Introduction: In response to the ongoing shift of the regulatory cardiac safety paradigm, a recent White Paper proposed general principles for developing and implementing proarrhythmia risk prediction models. These principles...
5.
Ridder B, Leishman D, Bridgland-Taylor M, Samieegohar M, Han X, Wu W, et al.
Toxicol Appl Pharmacol
. 2020 Apr;
395:114983.
PMID: 32247767
No abstract available.
6.
Kramer J, Himmel H, Lindqvist A, Stoelzle-Feix S, Chaudhary K, Li D, et al.
Sci Rep
. 2020 Mar;
10(1):5627.
PMID: 32221320
Automated patch clamp (APC) instruments enable efficient evaluation of electrophysiologic effects of drugs on human cardiac currents in heterologous expression systems. Differences in experimental protocols, instruments, and dissimilar site procedures...
7.
Ridder B, Leishman D, Bridgland-Taylor M, Samieegohar M, Han X, Wu W, et al.
Toxicol Appl Pharmacol
. 2020 Mar;
394:114961.
PMID: 32209365
Introduction: hERG block potency is widely used to calculate a drug's safety margin against its torsadogenic potential. Previous studies are confounded by use of different patch clamp electrophysiology protocols and...
8.
Li Z, Ridder B, Han X, Wu W, Sheng J, Tran P, et al.
Clin Pharmacol Ther
. 2018 Aug;
105(2):466-475.
PMID: 30151907
The International Council on Harmonization (ICH) S7B and E14 regulatory guidelines are sensitive but not specific for predicting which drugs are pro-arrhythmic. In response, the Comprehensive In Vitro Proarrhythmia Assay...
9.
Obejero-Paz C, Bruening-Wright A, Kramer J, Hawryluk P, Tatalovic M, Dittrich H, et al.
Sci Rep
. 2015 Dec;
5:17623.
PMID: 26616666
Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacked efficacy. Although a potent blocker of hERG, it produced no serious adverse events. We attributed the...
10.
Weyand B, Israelowitz M, Kramer J, Bodmer C, Noehre M, Strauss S, et al.
Biomed Res Int
. 2015 Aug;
2015:320280.
PMID: 26301245
A three-dimensional computational fluid dynamics- (CFD-) model based on a differential pressure laminar flow bioreactor prototype was developed to further examine performance under changing culture conditions. Cell growth inside scaffolds...